LAG3 and central nervous system cancer: Further profiling of tumor – immune system interactions is warranted in glioma, as only a small subset of patients responded in so far conducted immunotherapy trials and reliable biomarkers to identify benefitting patients from immune modulatory treatment modalities including LAG-3 blockade are still needed.